However, recent identification of p27Kip1 mutations in breast cancer [10] and multiple endocrine neoplastic syndromes [11] raises an interesting new possibility that mutational inactivation of p27Kip1 in other tumour types cannot be completely ruled out [12]. This evidence concerns the gene CDKN1B and breast carcinoma.